Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $19.67.

A number of research analysts recently weighed in on the company. Barclays raised their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Wednesday, July 10th. Finally, JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently bought and sold shares of the business. Janney Montgomery Scott LLC increased its stake in Teva Pharmaceutical Industries by 13.6% in the first quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock valued at $19,366,000 after acquiring an additional 164,614 shares during the period. QRG Capital Management Inc. lifted its position in shares of Teva Pharmaceutical Industries by 53.7% during the 1st quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after buying an additional 50,247 shares during the period. Capital Wealth Planning LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $2,169,000. SG Americas Securities LLC boosted its stake in Teva Pharmaceutical Industries by 12.0% in the 1st quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock valued at $8,613,000 after buying an additional 65,529 shares in the last quarter. Finally, Coronation Fund Managers Ltd. bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at $1,334,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $18.43 on Wednesday. The firm has a market cap of $20.87 billion, a price-to-earnings ratio of -44.95, a price-to-earnings-growth ratio of 1.29 and a beta of 0.88. The company’s fifty day moving average is $18.01 and its 200-day moving average is $16.83. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries has a 12 month low of $8.23 and a 12 month high of $19.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. Equities analysts expect that Teva Pharmaceutical Industries will post 2.33 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.